Article
Enterolactone has stronger effects than enterodiol on ovarian cancer
24 Jul 2017
Abstract excerpt
BACKGROUND: Ovarian cancer is one of the three leading gynecological malignancies, characterized by insidious growth, highly frequent metastasis, and quick development of drug resistance. As a result, this disease has low 5-year survival rates. Estrogen receptor inhibitors were commonly used for the treatment, but only 7% to 18% of patients respond to anti-estrogen therapies. Therefore, more effective therapies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
